Oturkibart Posts 74.5% Itch Response in Phase 3 Prurigo Nodularis Trial
Phase 3 results from 412 Chinese patients show oturkibart, an IL-4Rα monoclonal antibody, drove 74.5% of participants to a 4-point WI-NRS reduction at 24 weeks versus 29% on placebo, with benefits su…